Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT01576666. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT01576666
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
- Advanced Pancreatic Adenocarcinoma
- Advanced Solid Tumors
- Dose Escalation
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
- Preliminary Efficacy
- Recurrent Glioblastoma Multiforme
- Safety
- Triple Negative Metastatic Breast Cancer
Interventions
- BKM120 Drug
- LDE225 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2012
- Primary completion
- Mar 31, 2015
- Completion
- Mar 31, 2015
- Last update posted
- Dec 18, 2020
2012 – 2015
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars Sinai Medical Center SC | Los Angeles | California | 90048 | — |
| University of California San Francisco UCSF (SC) | San Francisco | California | 94101 | — |
| H. Lee Moffitt Cancer Center & Research Institute Moffitt 4 | Tampa | Florida | 33612 | — |
| Dana Farber Cancer Institute Dana SC | Boston | Massachusetts | 02215 | — |
| Mayo Clinic - Rochester Division of Hematology | Rochester | Minnesota | 55905 | — |
| Duke University Medical Center Duke - Baker | Durham | North Carolina | 27710 | — |
| Willamette Valley Clinical Studies Williamette Valley Cancer | Eugene | Oregon | 97404 | — |
| Northwest Cancer Specialists Northwest Cancer | Portland | Oregon | 97210 | — |
| Fox Chase Cancer Center FCCC | Philadelphia | Pennsylvania | 19111-2497 | — |
| Texas Oncology Midtown Texas Oncology | Dallas | Texas | 75251 | — |
| Sammons Cancer Center - Texas Oncology SC-2 | Dallas | Texas | 78246 | — |
| University of Texas/MD Anderson Cancer Center SC-3 | Houston | Texas | 77030-4009 | — |
| University of Utah / Huntsman Cancer Institute Huntsman | Salt Lake City | Utah | 84103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01576666, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2020 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01576666 live on ClinicalTrials.gov.